August 25, 2024Open Access

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

We report 5-year efficacy and safety outcomes from CheckMate 9LA in patients with metastatic non-small cell lung cancer (mNSCLC) and exploratory analyses in key patient subgroups.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Reck et al. (Sun,) studied this question.

synapsesocial.com/papers/68e5b019b6db643587549438 https://doi.org/https://doi.org/10.1016/j.ejca.2024.114296

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial2024 · 62 citations
2PD-1 <sup>+</sup> regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer2019 · 1,029 citations
3OA14.05 5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%2023 · 7 citations
4EP11.03-23 Efficacy of Nivolumab + Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: a Network Meta-analysis2023 · 1 citations
5Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.12023 · 50 citations

Me gusta

Guardar

Ver artículo completo